ClinicalTrials.gg

Conjunctivitis, Allergic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 211 studies for Conjunctivitis, Allergic across more than 10 countries. 19 are recruiting or about to start. 174 of them are mainly about Conjunctivitis, Allergic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
157
Status unknown
16
Recruiting
12
Terminated
9
Withdrawn
6
Not yet recruiting
6

Phase

Phase 3
72
Phase 2
52
Phase 4
42
Phase 1
12

Where

United States
95
Canada
14
Italy
11
Japan
11
France
10
Spain
9

Who develops what

Add Conjunctivitis, Allergic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 4 companies, 8 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Regeneron Pharmaceuticals, Dompé Farmaceutici S.p.A and Laboratoires Thea here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CyclosporineRecent, limited
Evidence
  • NCT07169695 · Laboratoires Thea · Phase 2 · live · comparator · “Ciclosporin” · registered Sep 2025
Novartis23% of its industry studiesUS: off-patent, 15 generics marketedEU: Santen Pharmaceutical Co., Ltd. (EMA 2015) + 1 other11 study
brimonidineRecent, limited
Evidence
  • NCT05579730 · Bausch Health Companies Inc. · Phase 3 · comparator · “Brimonidine Tartrate 0.025%” · registered Oct 2022
AbbVie41% of its industry studiesUS: off-patent, 27 generics marketedEU: Galderma Group AG (EMA 2014)11 study
olopatadineEarlier only
Evidence
  • NCT04776096 · laboratorios poen · Phase 4 · comparator · “Olopatadine Hydrochloride 0.2% BAK” · registered Feb 2021
  • NCT03320434 · ORA, Inc. · Phase 2 · comparator · “Patanol” · registered Oct 2017
  • NCT02161146 · AbbVie · Phase 3 · comparator · “Olopatadine” · registered Jun 2014
  • NCT01657240 · Laboratorios Sophia S.A de C.V. · Phase 3 · comparator · “Olopatadine Hydrochloride” · registered Jul 2012
  • NCT01435460 · Bausch Health Companies Inc. · Phase 3 · comparator · “Olopatadine 0.1%” · registered Sep 2011
Alcon76% of its industry studiesUS: off-patent, 22 generics marketedEU: Novartis (EMA 2002)00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
cenegerminApproved: EU 2017☆ Track1 live phase-3 study: NCT07519902Dompé Farmaceutici S.p.A
REGN-2Cat☆ Track1 live phase-3 study: NCT07675811Regeneron Pharmaceuticals
freneslerbart☆ Track1 live phase-3 study: NCT07675811Regeneron Pharmaceuticals
mevonlerbart☆ Track1 live phase-3 study: NCT07675811Regeneron Pharmaceuticals

The 4 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 21 Jan 2027 est.T1695 · Laboratoires Thea · Phase 2 main aim+ T1695 vs CyclosporineNCT07169695 A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis — primary endpoint: Change from baseline (Day 1) at Day 29 (Week 4) in Corneal Fluorescein Staining (CFS) grade assessed by the (0-5) modified Oxford scale in the study eye. · 120 enrolled
  • Mar 2027 est.TL-925 · Telios Pharma, Inc. · Phase 2 main aimNCT07938632 TL-925 for the Treatment of Allergic Conjunctivitis — primary endpoint: Ocular Itching Score · 100 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Conjunctivitis, Allergic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Calcineurin inhibitors 1 open · Antihistamines 59 · Corticosteroids 10

Coming up

7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger. 4 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (17%) take healthy volunteers.

Recruiting studies that take each age, of 12
AgeWomenMen
104 (33%)4 (33%)
1811 (92%)11 (92%)
3011 (92%)11 (92%)
4011 (92%)11 (92%)
5010 (83%)10 (83%)
659 (75%)9 (75%)
758 (67%)8 (67%)
858 (67%)8 (67%)

Across all 211 studies, recruiting or not: 25% stop at 75 or younger and 24% at 65; 45% take children; 0% are for women only and 0% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Conjunctivitis, Allergic studies take

Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 36 mo4–14 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 211. Browse all 211 → or search them.